Department of Psychiatry, Indiana University, 355 W 16th St.,, Indianapolis, IN, 46202, USA.
Department of Psychiatry, University of Iowa, Iowa City, IA, USA.
Soc Psychiatry Psychiatr Epidemiol. 2023 Oct;58(10):1503-1508. doi: 10.1007/s00127-023-02448-6. Epub 2023 Mar 6.
Psychedelics are being explored for their potential therapeutic benefits across a wide range of psychiatric diagnoses and may usher in a new age in psychiatric treatment. There is stigma associated with these currently illegal substances, and use varies by race and age. We hypothesized that minoritized racial and ethnic populations, relative to White respondents, would perceive psychedelic use as riskier.
Using 2019 cross-sectional data from the National Survey of Drug Use and Health, we conducted a secondary analysis of 41,679 respondents. Perceived risk of heroin was used as a surrogate for overall risk of illegal substance use; heroin and lysergic acid diethylamide were the only substances queried this way in the sample.
A majority regarded lysergic acid diethylamide (66.7%) and heroin (87.3%) as a great risk if used once or twice. There were clear differences by race, with White respondents and those indicating more than one race having significantly lower perceived risk of lysergic acid diethylamide than respondents from other groups. Perceived risk of use also significantly increased with age.
Perceived risk of lysergic acid diethylamide is unevenly distributed across the population. Stigma and racial disparities in drug-related crimes likely contribute to this. As research into potential therapeutic indications for psychedelics continues, perceived risk of use may change.
迷幻剂在广泛的精神诊断中因其潜在的治疗益处而受到探索,可能开创精神治疗的新时代。这些目前非法的物质带有污名,而且使用情况因种族和年龄而异。我们假设,与白人受访者相比,少数民族和族裔群体将认为迷幻剂的使用风险更大。
我们使用了 2019 年全国毒品使用和健康调查的横断面数据,对 41679 名受访者进行了二次分析。将海洛因的感知风险用作非法物质使用总体风险的替代指标;在样本中,只有海洛因和麦角酸二乙酰胺是通过这种方式查询的物质。
大多数人认为麦角酸二乙酰胺(66.7%)和海洛因(87.3%)如果使用一次或两次,风险极大。种族差异明显,白人受访者和表示多种族的受访者比其他群体的受访者对麦角酸二乙酰胺的感知风险明显更低。使用的感知风险也随着年龄的增长而显著增加。
麦角酸二乙酰胺的感知风险在人群中分布不均。与毒品相关犯罪的污名和种族差异可能导致了这种情况。随着对迷幻剂潜在治疗适应症的研究继续进行,使用的感知风险可能会发生变化。